Susan Bobulsky Sells Shares of Adaptive Biotechnologies
Susan Bobulsky, Chief Commercial Officer, sold 5,000 shares in a planned transaction.
Key Points
- Susan Bobulsky, Chief Commercial Officer at Adaptive Biotechnologies, sold 5,000 shares for $102,500 on June 25, 2026.
- Shares of Adaptive Biotechnologies traded near $21.18 on Tuesday, with a market cap of $3.35 billion and a 52-week high of $21.01.
- Guggenheim maintained a 'buy' rating with a $22 target, while insiders and funds adjusted their positions in recent transactions.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 25, 2026, Susan Bobulsky, the Chief Commercial Officer for Minimal Residual Disease at Adaptive Biotechnologies Corporation, sold 5,000 shares of the company. This planned transaction was executed at an average price of $20.50 per share, totaling $102,500.
Insider Buying and Selling at Adaptive Biotechnologies Corporation
In addition to Susan Bobulsky's transaction, several other insider trades occurred recently. Michelle Renee Griffin executed multiple trades on the same day, selling 52,084 shares at $20.18 each, and purchasing an equal number at $7.80 per share, outside of a planned arrangement. Meanwhile, Harlan Robins, Chief Scientific Officer, sold 6,160 shares at $18.01 on June 16 and 100,000 shares at $17.37 on June 15, both under planned transactions.
Other Institutional Activity in Adaptive Biotechnologies
Several institutional investors have made moves with their Adaptive Biotechnologies holdings. Viking Global Investors LP maintained its position with 29,993,708 shares valued at approximately $416.3 million. BlackRock, Inc. slightly reduced its stake by 30,534 shares, ending with 13,303,025 shares worth about $184.6 million. Vanguard Capital Management LLC opened a new position with 6,094,144 shares valued at roughly $84.6 million. Similarly, Vanguard Portfolio Management LLC also initiated a stake, acquiring 4,491,474 shares valued at $62.3 million. Meanwhile, Westfield Capital Management Co LP increased its holdings by 1,376,237 shares to a total of 5,436,718 shares, valued at approximately $75.5 million, and Invesco Ltd. boosted its stake by 1,342,413 shares for a total of 4,450,066 shares worth about $61.8 million.
Adaptive Biotechnologies Corporation Stock Down 15.9%
Shares of NasdaqGS:ADPT traded near $21.18 on Tuesday. Adaptive Biotechnologies has a market cap of approximately $3.35 billion. The stock's forward P/E ratio is not meaningful due to the company's lack of profitability, and it has a beta of 2.151. Over the past 52 weeks, the stock has ranged from a low of $9.96 to a high of $21.01. The company maintains a 50-day moving average of $15.32 and a 200-day moving average of $15.62. It has a strong liquidity position with a current ratio of 3.35 and a quick ratio of 3.08, though it carries a high debt-to-equity ratio of 92.84.
$ADPT stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Adaptive Biotechnologies reported revenue of $295.4 million, reflecting a growth rate of 35.1%. The company, however, recorded a net margin of -16.8% and a return on equity of -23.96%. The next earnings report is expected on August 4, 2026.
Analysts Set New Price Targets
On June 29, 2026, Guggenheim maintained its 'buy' rating for Adaptive Biotechnologies with a price target of $22. Other analysts have also weighed in, with Morgan Stanley maintaining a 'hold' rating and a target of $18, and JP Morgan reiterating a 'buy' rating with a target of $19. The overall consensus leans towards a 'strong buy', with a mean target price of $20.29 based on seven analyst opinions.
About Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation, based in Seattle, Washington, operates in the healthcare sector, specifically within diagnostics and research. The company, led by CEO Chad M. Robins, employs 624 people. It develops an immune medicine platform for diagnosing and treating various diseases. Its immunosequencing platform uses proprietary chemistry, computational biology, and machine learning to analyze the adaptive immune system. Key offerings include the clonoSEQ diagnostic test for monitoring Minimal Residual Disease (MRD) in cancer patients and other products for life sciences research, clinical diagnostics, and drug discovery.
Bottom Line
Susan Bobulsky's recent share sale is part of a planned transaction, indicating regular insider activity at Adaptive Biotechnologies. Investors keep a close watch on these transactions as they can provide insights into insider sentiment. However, it's important to remember that these insider sales do not necessarily predict future stock performance. The company's upcoming earnings report on August 4 will be another key event for stakeholders to assess its financial health and growth prospects.
Get Adaptive Biotechnologies Corporation alerts
New 13F filings, insider trades, and analyst moves on $ADPT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.